SCHEMBL4575202

SCHEMBL4575202

CCCc1c(-c2cc(=O)c3c(O)c(CCC)c(OCC(O)CO)cc3o2)ccc(OC)c1O

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.42
CYP1B1 Q16678 2/20 0.42
CYP1A2 P05177 1/20 0.42
OPRD1 P41143 1/20 0.42
FLT3 P36888 2/20 0.41
AURKA O14965 1/20 0.41
KDR P35968 1/20 0.41
AURKB Q96GD4 1/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
ADORA3 P0DMS8 1/20 0.40
ABCB1 P08183 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
AKT1 P31749 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8308340 0.89 BRD4 (0.43) CYP1A2KDM4EPOLBMAPTABCB1
SCHEMBL8309780 0.88 BRD4 (0.46) KDM4EPOLBMAPTABCB1ABCG2
SCHEMBL4574734 0.88 CYP1B1 (0.46) CYP1A1CYP1B1CYP1A2FLT3KDR
SCHEMBL4575066 0.88 CYP1B1 (0.46) CYP1A1CYP1B1CYP1A2FLT3KDR
SCHEMBL4575775 0.88 CYP1B1 (0.46) CYP1A1CYP1B1CYP1A2FLT3KDR
SCHEMBL8305275 0.87 AKT1 (0.42) CYP1A1CYP1B1CYP1A2OPRD1FLT3
SCHEMBL8308179 0.82 HDAC6 (0.51) CYP1A1CYP1B1CYP1A2OPRD1FLT3
SCHEMBL8859603 0.82 BRD4 (0.39) KDM4EPOLBMAPT
SCHEMBL8859601 0.82 BRD4 (0.39) KDM4EPOLBMAPT
SCHEMBL8306985 0.79 BRD4 (0.47) KDM4EPOLBMAPTABCB1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0709383-B1 Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-12-15 EP claimed
US-5629339-A CHRONIC VENOUS INSUFFICIENCY ADIR ET COMPAGNIE (FR) 1997-05-13 US claimed
EP-0709383-A1 Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1996-05-01 EP claimed
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies LES LABORATOIRES SERVIER (FR) 2008-07-24 US disclosed
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies LES LABORATOIRES SERVIER (FR) 2008-07-24 US disclosed
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies LES LABORATOIRES SERVIER (FR) 2008-07-24 US disclosed
EP-0709383-B1 Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-12-15 EP disclosed
US-5629339-A CHRONIC VENOUS INSUFFICIENCY ADIR ET COMPAGNIE (FR) 1997-05-13 US disclosed
EP-0709383-A1 Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1996-05-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies ADAMTS13, ADAMTS1, SERPINC1 CYP1A1 545/4885CYP1B1 340/4885CYP1A2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.